Miniatura

Fitxers

L20_2020_EMBO Molecular Medicine_e13426_OA.pdf (1.45 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-12-14

Llicència de publicació

cc by (c) Monteil et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172999

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.15252/emmm.202013426

Resum

There is a critical need for safe and effective drugs for COVID-19. Only remdesivir has received authorization for COVID-19 and has been shown to improve outcomes but not decrease mortality. However, the dose of remdesivir is limited by hepatic and kidney toxicity. ACE2 is the critical cell surface receptor for SARS-CoV-2. Here, we investigated additive effect of combination therapy using remdesivir with recombinant soluble ACE2 (high/low dose) on Vero E6 and kidney organoids, targeting two different modalities of SARS-CoV-2 life cycle: cell entry via its receptor ACE2 and intracellular viral RNA replication. This combination treatment markedly improved their therapeutic windows against SARS-CoV-2 in both models. By using single amino-acid resolution screening in haploid ES cells, we report a singular critical pathway required for remdesivir toxicity, namely, Adenylate Kinase 2. The data provided here demonstrate that combining two therapeutic modalities with different targets, common strategy in HIV treatment, exhibit strong additive effects at sub-toxic concentrations. Our data lay the groundwork for the study of combinatorial regimens in future COVID-19 clinical trials.

Matèries

SARS-CoV-2, Assaigs clínics

Matèries (anglès)

SARS-CoV-2, Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
<b>Publicacions de projectes de recerca finançats per la UE</b>

Citació

MONTEIL, Vanessa, DYCZYNSKI, Matheus, LAUSCHKE, Volker m., KWON, Hyesoo, WIRNSBERGER, Gerald, YOUHANNA, Sonia, ZHANG, Haibo, SLUTSKY, Arthur s., HURTADO DEL POZO, Carmen, HORN, Moritz, MONTSERRAT, Núria, PENNINGER, Josef m., MIRAZIMI, Ali. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. _EMBO Molecular Medicine_. 2020. Vol. 13, núm. e13426. [consulta: 21 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/172999]

Exportar metadades

JSON - METS

Compartir registre